Brevetti Angela and 3CK develop compact prefilled single use syringe for safe self injection

Brevetti Angela has joined forces with sister company 3CK to develop a compact prefilled autodisable device (CPAD) squeezable single-use syringe for US-based non-profit global health organization PATH to develop for worldwide distribution.

The ultra-simple and user-friendly device is designed for mass production and aseptic filling using BFS (Blow-Fill-Seal) technology for cost-efficient provision to low- and middle-income markets, particularly for mass vaccination and contraception campaigns.

Auto disabling feature

The CPAD design overcomes current difficulties in usability and aseptic filling with a simple squeezable injection action and prefillable format, being suitable for ‘one pass’ forming, filling, and sealing on a BFS system.

A particular feature of the design is that the CPAD syringe will also be auto disabling in that once the dose is administered, the device will be locked, and therefore impossible to reuse. This eliminates the possibility of tampering with the device, avoiding any risks of contamination, overdosing, or counterfeiting.

CPAD advantages

The CPAD design has many advantages, being inexpensive to produce, and easy and safe to use. The syringe does not need to be pre-sterilized as it is produced in an aseptic environment, and it comes pre-assembled with no need for needle preparation or filling from vial.

Injection merely requires a simple squeezing action with low pinch force required, while the prefilled format also ensures correct dose quantity. These features make self-injection realistic for all patients.

Other benefits of the CPAD design include:
• Large labeling area
• Compact dimensions
• High Sterility Assurance Level
• Discreet self-administration

Concept to reality

The CPAD concept was first devised by the PATH team in Seattle USA, which awarded a grant to 3CK to develop a novel design based on its target product profile. The scope was to improve the functionality, reduce the cost and provide higher sterility assurance: this was achieved by a design which could be produced on a BFS machine.

The design program harness Brevetti Angela’s industry-leading experience in Blow-Fill-Seal technology with its SYFPAC BFS platforms, along with 3CK’s capabilities in developing innovative prefilled syringe (PFS) solutions, such as its O-Flow silicone-free design.

The project is currently on the final prototyping stage and production is scheduled to kick-off in a few months.

Resources

Click on Brevetti Angela SYFPAC® BFS Technology to learn more.
Click on 3CK PFS technology for further information.
Click on PATH Global Mission to learn more.